Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Gross Margin (2023 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Gross Margin for 3 consecutive years, with 94.7% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 6068.0% year-over-year to 94.7%, compared with a TTM value of 123.97% through Sep 2025, up 3703.0%, and an annual FY2024 reading of 93.3%, down 77.0% over the prior year.
  • Gross Margin was 94.7% for Q3 2025 at Fennec Pharmaceuticals, up from 89.98% in the prior quarter.
  • Across five years, Gross Margin topped out at 242.56% in Q4 2024 and bottomed at 34.03% in Q3 2024.
  • Average Gross Margin over 3 years is 102.2%, with a median of 94.7% recorded in 2025.
  • Peak annual rise in Gross Margin hit 14960bps in 2024, while the deepest fall reached -6089bps in 2024.
  • Year by year, Gross Margin stood at 92.96% in 2023, then soared by 161bps to 242.56% in 2024, then crashed by -61bps to 94.7% in 2025.
  • Business Quant data shows Gross Margin for FENC at 94.7% in Q3 2025, 89.98% in Q2 2025, and 95.74% in Q1 2025.